LBRX Stock Analysis: LB Pharmaceuticals Common | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 958m USD | 12M Return: 104.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 8.41M
Warnings
Tailwinds
Seasonality 0.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
LB Pharmaceuticals Inc (NASDAQ: LBRX) is a clinical-stage biopharmaceutical company headquartered in New York, NY, founded in 2015. The company is focused on developing therapies for neuropsychiatric conditions, with its lead candidate LB-102, an oral small molecule, advancing through multiple clinical programs. LB-102 is currently in Phase 3 trials for acute schizophrenia, has completed Phase 2 for bipolar I depression, is being studied as adjunctive treatment for major depressive disorder (MDD), and is in pre-clinical development as a long-acting injectable (LAI) formulation. As a clinical-stage company, LB Pharmaceuticals has not yet commercialized a product and depends on capital markets to fund its research and development pipeline. The company completed its IPO on September 11, 2025, and operates in the pharmaceuticals sub-industry within the broader health care sector, an area characterized by high unmet medical need and lengthy development timelines.
- Phase 3 schizophrenia data for LB-102 approaches readout
- Pipeline expands into bipolar depression and MDD indications
- Cash burn rate signals potential dilutive share offering
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.13 > 0.02 and ΔFCF/TA 259.2 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.13 > 3% & CFO -50.4m > Net Income -39.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 35.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (28.2m) vs 12m ago 11.1k% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.96 (Total Current Assets 389.1m - Total Current Liabilities 10.9m) / Total Assets 393.5m |
| B: -0.38 (Retained Earnings -148.6m / Total Assets 393.5m) |
| C: -0.19 (EBIT TTM -39.4m / Avg Total Assets 206.4m) |
| D: 25.61 (Book Value of Equity 378.7m / Total Liabilities 14.8m) |
| Altman-Z'' = 30.68 = AAA |
As of July 08, 2026, the stock is trading at USD 34.29 with a total of 412,098 shares traded. Over the past week, the price has changed by +5.06%, over one month by +16.63%, over three months by +35.53% and over the past year by +104.11%.
Current recommended Stop Loss: 31.80 (which is 7.3% or 1.4 ATR below the current price).
LB Pharmaceuticals Common has no consensus analysts rating.
P/B = 2.5315
Revenue TTM = 0.0 USD
EBIT TTM = -39.4m USD
EBITDA TTM = -39.0m USD
Long Term Debt = 2.74m USD (estimated: total debt 3.47m - short term 730k)
Short Term Debt = 730k USD (from shortTermDebt, last quarter)
Debt = 3.47m USD (from shortLongTermDebtTotal, last quarter) (leases 3.47m already included)
Net Debt = -362.2m USD (calculated: Debt 3.47m - CCE 365.6m)
Enterprise Value = 595.9m USD (958.1m + Debt 3.47m - CCE 365.6m)
Interest Coverage Ratio = unknown (Ebit TTM -39.4m / Interest Expense TTM 0.0)
EV/FCF = -11.82x (Enterprise Value 595.9m / FCF TTM -50.4m)
FCF Yield = -8.46% (FCF TTM -50.4m / Enterprise Value 595.9m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 321k) / Revenue TTM)
Tobins Q-Ratio = 1.51 (Enterprise Value 595.9m / Total Assets 393.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 3.47m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -31.1m (EBIT -39.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 35.68 (Total Current Assets 389.1m / Total Current Liabilities 10.9m)
Debt / Equity = 0.01 (Debt 3.47m / totalStockholderEquity, last quarter 378.7m)
Debt / EBITDA = 9.27 (negative EBITDA) (Net Debt -362.2m / EBITDA -39.0m)
Debt / FCF = 7.18 (negative FCF - burning cash) (Net Debt -362.2m / FCF TTM -50.4m)
Total Stockholder Equity = 221.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -18.98% (Net Income -39.2m / Total Assets 393.5m)
RoE = -17.68% (Net Income TTM -39.2m / Total Stockholder Equity 221.6m)
RoCE = -17.55% (EBIT -39.4m / Capital Employed (Equity 221.6m + L.T.Debt 2.74m))
RoIC = -8.12% (negative operating profit) (NOPAT -31.1m / Invested Capital 383.3m)
WACC = 9.94% (E(958.1m)/V(961.6m) * Re(9.98%) + D(3.47m)/V(961.6m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.98% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 45.73 | Cagr: 182.4%
[DCF] Fair Price = unknown (Cash Flow -50.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.81 | Chg30d=+1.28% | Revisions=+29% | Analysts=5
EPS next Quarter (2026-09-30): EPS=-0.95 | Chg30d=-0.58% | Revisions=+57% | Analysts=5
EPS current Year (2026-12-31): EPS=-3.51 | Chg30d=-0.29% | Revisions=+57% | GrowthEPS=-12.2% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-4.49 | Chg30d=+0.04% | Revisions=+0% | GrowthEPS=-27.9% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +53% (up=13, down=3)